DNB Bioteknologi A
Equity fund
1 year
No data to display ...
Largest region
High
Risk
Annual costs
Morningstar
Partial
Sustainability
Development
Last 5 years
( ann.)
Details
- Fondet er et aksjefond som investerer hovedsakelig i aksjer (verdipapirer som representerer en eierandel i et selskap) notert på børser og regulerte markeder over hele verden, innenfor sektorene bioteknologi, diagnostikk, farmasi, produksjon av farmasøytiske produkter, biologiske legemidler herunder genterapi, og annen helserelatert virksomhet. Det vil også være anledning til å investere innenfor selskaper som har deler av sitt virke tilknyttet helse.
Investment horizon
- DNB Bioteknologi A is a Equity fund. This mutual fund type is suitable for those who plan to save for at least 6 years.
Characteristics
- Minimum amount
- Sharpe 3 years
- NAV/Price
01 Jul 2026
- Margin rate
- Start date04 May 2020
- ISINNO0010877707
Risk
- High (5 of 7)
Morningstar rating
- The Morningstar Rating is an objective standard that tells us how well a fund has done compared to similar funds. If a fund performs better than other funds it is compared with, it receives a high rating. Correspondingly, a fund receives a low rating if it performs worse than similar funds.
Sustainability
- SustainabilityPartial
Annual cost
- Ongoing costs
Includes management fees of 0,85 %
- Platform fee
- Kickback fee
- Annual running costs
Other costs
- Performance-based fee
- Transaction costs
Costs for any currency exchanges are not included.
Allocation
- Stocks 98%Interest 2%
Portfolio
Shows the fund's largest investments.
- argenx SE7.2%
- BioMarin Pharmaceutical Inc6.3%
- Revolution Medicines Inc Ordinary Shares4.5%
- Axsome Therapeutics Inc4.4%
- Neurocrine Biosciences Inc4.0%
- Insmed Inc3.8%
- UCB SA3.5%
- Ionis Pharmaceuticals Inc3.0%
- Rhythm Pharmaceuticals Inc3.0%
- Roivant Sciences Ltd Ordinary Shares2.8%